<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04151628</url>
  </required_header>
  <id_info>
    <org_study_id>CP 62611</org_study_id>
    <nct_id>NCT04151628</nct_id>
  </id_info>
  <brief_title>Disrupt CAD IV With the Shockwave Coronary IVL System</brief_title>
  <official_title>Prospective, Multicenter, Single-Arm Study of the SWM-1234 in Calcified Coronary Arteries (Disrupt CAD IV Study - Japan)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shockwave Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shockwave Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study design is a prospective, multicenter, single-arm study to evaluate the safety and&#xD;
      effectiveness of the Shockwave Medical Coronary Intravascular Lithotripsy (IVL) System in de&#xD;
      novo, calcified, stenotic coronary arteries prior to stenting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subject Population: Subjects ≥ 18 years of age with de novo, calcified coronary artery&#xD;
      lesions presenting with stable, unstable or silent ischemia that are suitable for&#xD;
      percutaneous coronary intervention. Approximately 72 subjects at 8 sites in Japan will be&#xD;
      enrolled. Subjects will be followed through discharge, 30 days, 6, 12 and 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 6, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Actual">May 8, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The Coronary IVL System is a proprietary balloon catheter system designed to enhance stent outcomes by enabling delivering of the calcium disrupting capability of lithotripsy prior to balloon dilatation at low pressures. The Coronary IVL System consists of an IVL Balloon Catheter with 2 integrated emitters, a Lithotripsy Generator, and a Connector Cable.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced Freedom From MACE Within 30 Days Post-procedure</measure>
    <time_frame>Within 30 days of index procedure</time_frame>
    <description>The primary safety endpoint was freedom from major adverse cardiac events (MACE) at 30 days - a composite of cardiac death, myocardial infarction (MI) and target vessel revascularization (TVR). The primary endpoints were analyzed using the Intent To Treat (ITT) population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With Procedural Success</measure>
    <time_frame>12-24 hours post procedure or at discharge, whichever is earlier, but at least 6 hours post procedure</time_frame>
    <description>The primary effectiveness endpoint was Procedural Success defined as stent delivery with a residual in-stent stenosis &lt;50% (core laboratory assessed) and without in-hospital MACE</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Coronary Lithotripsy System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive lithotripsy treatment from the Shockwave Medical Coronary IVL System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lithotripsy</intervention_name>
    <description>Deliver Lithotripsy to the target vessel prior to placing a coronary stent</description>
    <arm_group_label>Coronary Lithotripsy System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is ≥18 years of age&#xD;
&#xD;
          2. Subjects with native coronary artery disease (including stable or unstable angina and&#xD;
             silent ischemia) suitable for PCI&#xD;
&#xD;
          3. For patients with unstable ischemic heart disease, biomarkers (troponin or CK-MB) must&#xD;
             be less than or equal to the upper limit of lab normal within 12 hours prior to the&#xD;
             procedure (note: if both labs are drawn both must be normal)&#xD;
&#xD;
          4. For patients with stable ischemic heart disease, biomarkers may be drawn prior to the&#xD;
             procedure or at the time of the procedure from the side port of the sheath.&#xD;
&#xD;
               1. If drawn prior to the procedure, biomarkers (troponin or CK- MB) must be less&#xD;
                  than or equal to the upper limit of lab normal within 12 hours prior to the index&#xD;
                  procedure (note: if both labs are drawn, both must be normal)&#xD;
&#xD;
               2. If biomarkers are drawn at the time of the procedure from the side port of the&#xD;
                  sheath prior to any intervention, biomarker results do not need to be analyzed&#xD;
                  prior to enrollment.&#xD;
&#xD;
          5. Left ventricular ejection fraction &gt; 25% within 6 months (note: in the case of&#xD;
             multiple assessments of LVEF, the measurement closest to enrollment will be used for&#xD;
             this criteria; may be assessed at time of index procedure)&#xD;
&#xD;
          6. Subject or legally authorized representative, signs a written Informed Consent form to&#xD;
             participate in the study, prior to any study-mandated procedures&#xD;
&#xD;
          7. Lesions in non-target vessels requiring PCI may be treated either:&#xD;
&#xD;
               1. &gt;30 days prior to the study procedure if the procedure was unsuccessful or&#xD;
                  complicated; or&#xD;
&#xD;
               2. &gt;24 hours prior to the study procedure if the procedure was successful and&#xD;
                  uncomplicated (defined as a final lesion angiographic diameter stenosis &lt;30% and&#xD;
                  TIMI 3 flow (visually assessed) for all non-target lesions and vessels without&#xD;
                  perforation, cardiac arrest or need for defibrillation or cardioversion or&#xD;
                  hypotension/heart failure requiring mechanical or intravenous hemodynamic support&#xD;
                  or intubation, and with no post-procedure biomarker elevation&#xD;
&#xD;
                  &gt;normal; or&#xD;
&#xD;
               3. &gt;30 days after the study procedure&#xD;
&#xD;
             Angiographic Inclusion Criteria&#xD;
&#xD;
          8. The target lesion must be a de novo coronary lesion that has not been previously&#xD;
             treated with any interventional procedure&#xD;
&#xD;
          9. Single de novo target lesion stenosis of protected LMCA, or LAD, RCA or LCX (or of&#xD;
             their branches) with:&#xD;
&#xD;
               1. Stenosis of ≥70% and &lt;100% or&#xD;
&#xD;
               2. Stenosis ≥50% and &lt;70% (visually assessed) with evidence of ischemia via positive&#xD;
                  stress test, or fractional flow reserve value ≤0.80, or iFR &lt;0.90 or IVUS or OCT&#xD;
                  minimum lumen area ≤4.0 mm²&#xD;
&#xD;
         10. The target vessel reference diameter must be ≥2.5 mm and ≤4.0 mm&#xD;
&#xD;
         11. The lesion length must not exceed 40 mm&#xD;
&#xD;
         12. The target vessel must have TIMI flow 3 at baseline (visually assessed, may be&#xD;
             assessed after pre-dilatation)&#xD;
&#xD;
         13. Evidence of calcification at the lesion site by, a) angiography, with fluoroscopic&#xD;
             radio-opacities noted without cardiac motion prior to contrast injection involving&#xD;
             both sides of the arterial wall in at least one location and total length of calcium&#xD;
             of at least 15 mm and extending partially into the target lesion, OR by b) IVUS or&#xD;
             OCT, with presence of ≥270 degrees of calcium on at least 1 cross section&#xD;
&#xD;
         14. Ability to pass a 0.014&quot; guide wire across the lesion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any comorbidity or condition which may reduce compliance with this protocol, including&#xD;
             follow-up visits&#xD;
&#xD;
          2. Subject is a member of a vulnerable population including individuals with mental&#xD;
             disability, persons in nursing homes, children, impoverished persons, persons in&#xD;
             emergency situations, homeless persons, nomads, refugees, and those incapable of&#xD;
             giving informed consent.&#xD;
&#xD;
          3. Subject is participating in another research study involving an investigational agent&#xD;
             (pharmaceutical, biologic, or medical device) that has not reached the primary&#xD;
             endpoint&#xD;
&#xD;
          4. Subject is pregnant or nursing (a negative pregnancy test is required for women of&#xD;
             child-bearing potential within 7 days prior to enrollment)&#xD;
&#xD;
          5. Unable to tolerate dual antiplatelet therapy (i.e., aspirin, and either clopidogrel,&#xD;
             prasugrel, or ticagrelor) for at least 6 months&#xD;
&#xD;
          6. Subject has an allergy to imaging contrast media which cannot be adequately&#xD;
             pre-medicated&#xD;
&#xD;
          7. Subject experienced an acute MI (STEMI or non-STEMI) within 30 days prior to index&#xD;
             procedure, defined as a clinical syndrome consistent with an acute coronary syndrome&#xD;
             with troponin or CK- MB greater than 1 times the local laboratory's upper limit of&#xD;
             normal&#xD;
&#xD;
          8. New York Heart Association (NYHA) class III or IV heart failure&#xD;
&#xD;
          9. Renal failure with serum creatinine &gt;2.5 mg/dL, or chronic dialysis&#xD;
&#xD;
         10. History of a stroke or transient ischemic attack (TIA) within 6 months, or any prior&#xD;
             intracranial hemorrhage or permanent neurologic deficit&#xD;
&#xD;
         11. Active peptic ulcer or upper gastrointestinal (GI) b≥leeding within 6 months&#xD;
&#xD;
         12. Untreated pre-procedural hemoglobin &lt;10 g/dL or intention to refuse blood transfusions&#xD;
             if one should become necessary&#xD;
&#xD;
         13. Coagulopathy, including but not limited to platelet count &lt;100,000 or International&#xD;
             Normalized ratio (INR) &gt;1.7 (INR is only required in subjects who have taken warfarin&#xD;
             within 2 weeks of enrollment)&#xD;
&#xD;
         14. Subject has a hypercoagulable disorder such as polycythemia vera, platelet count&#xD;
             &gt;750,000 or other disorders&#xD;
&#xD;
         15. Uncontrolled diabetes defined as a HbA1c ≥10%&#xD;
&#xD;
         16. Subject has an active systemic infection on the day of the index procedure with either&#xD;
             fever, leukocytosis or requiring intravenous antibiotics&#xD;
&#xD;
         17. Subjects in cardiogenic shock or with clinical evidence of left-sided heart failure&#xD;
             (S3 gallop, pulmonary rales, oliguria, or hypoxemia)&#xD;
&#xD;
         18. Uncontrolled severe hypertension (systolic BP &gt;180 mm Hg or diastolic BP &gt;110 mm Hg)&#xD;
&#xD;
         19. Subjects with a life expectancy of less than 1 year&#xD;
&#xD;
         20. Non-coronary interventional (e.g., TAVR, MitraClip, or PFO occlusion, etc.) or&#xD;
             surgical structural heart procedures within 30 days prior to the index procedure&#xD;
&#xD;
         21. Planned non-coronary interventional (e.g., TAVR, MitraClip, or PFO occlusion, etc.) or&#xD;
             surgical structural heart procedures within 30 days after the index procedure&#xD;
&#xD;
         22. Subject refusing or not a candidate for emergency coronary artery bypass grafting&#xD;
             (CABG) surgery&#xD;
&#xD;
         23. Planned use of atherectomy, scoring or cutting balloon, or any investigational device&#xD;
             other than lithotripsy&#xD;
&#xD;
         24. Unprotected left main diameter stenosis &gt;30%&#xD;
&#xD;
         25. Target vessel is excessively tortuous defined as the presence of two or more bends&#xD;
             &gt;90º or three or more bends &gt;75º&#xD;
&#xD;
         26. Definite or possible thrombus (by angiography or intravascular imaging) in the target&#xD;
             vessel&#xD;
&#xD;
         27. Evidence of aneurysm in target vessel within 10 mm of the target lesion&#xD;
&#xD;
         28. Target lesion is an ostial location (LAD, LCX, or RCA, within 5 mm of ostium) or an&#xD;
             unprotected left main lesion&#xD;
&#xD;
         29. Target lesion is a bifurcation with ostial diameter stenosis ≥30%&#xD;
&#xD;
         30. Second lesion with &gt;50% stenosis in the same target vessel as the target lesion&#xD;
             including its side branches&#xD;
&#xD;
         31. Target lesion is located in a native vessel that can only be reached by going through&#xD;
             a saphenous vein or arterial bypass graft&#xD;
&#xD;
         32. Previous stent within the target vessel implanted within the last year&#xD;
&#xD;
         33. Previous stent within 10 mm of the target lesion regardless of the timing of its&#xD;
             implantation&#xD;
&#xD;
         34. Angiographic evidence of a dissection in the target vessel at baseline or after&#xD;
             guidewire passage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregg W Stone, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shigeru Saito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shonan Kamakura General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tenjinkai Shin-Koga Hospital</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka-Ken</state>
        <zip>830-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Higashi Tokushukai Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>065-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakurakai Takahashi Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo-Ken</state>
        <zip>654-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Higashi-Takarazuka Satoh Hospital</name>
      <address>
        <city>Takarazuka</city>
        <state>Hyogo-Ken</state>
        <zip>665-0873</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johas Kanto Rosai Hospital</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa-Ken</state>
        <zip>211-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan-Kamakura General Hospital</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto-Katsura Hospital</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto-Fu</state>
        <zip>615-8256</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyazaki Medical Association Hospital</name>
      <address>
        <city>Miyazaki</city>
        <state>Miyazaki-Ken</state>
        <zip>880-2102</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Saito S, Yamazaki S, Takahashi A, Namiki A, Kawasaki T, Otsuji S, Nakamura S, Shibata Y; Disrupt CAD IV Investigators. Intravascular Lithotripsy for Vessel Preparation in Severely Calcified Coronary Arteries Prior to Stent Placement - Primary Outcomes From the Japanese Disrupt CAD IV Study. Circ J. 2021 May 25;85(6):826-833. doi: 10.1253/circj.CJ-20-1174. Epub 2021 Feb 5.</citation>
    <PMID>33551398</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <results_first_submitted>March 12, 2021</results_first_submitted>
  <results_first_submitted_qc>June 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2021</results_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intravascular Lithotripsy</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT04151628/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study enrollment took place at 8 study centers in Japan between November 6, 2019 and April 6, 2020. A total of 72 subjects with de novo, calcified, stenotic coronary arteries were enrolled and treated with the Coronary Intravascular Lithotripsy (IVL) System</recruitment_details>
      <pre_assignment_details>72 subjects were consented and enrolled into the study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Roll-in</title>
          <description>The first subject enrolled at each site is considered a roll-in. Data on roll-in subjects were collected through 30 days.</description>
        </group>
        <group group_id="P2">
          <title>Intent to Treat (ITT)</title>
          <description>The Intent to Treat (ITT) population was the primary analysis cohort used to assess the primary safety and effectiveness endpoints. Data on the ITT population was collected through 30 days for primary endpoints. Long-term follow-up for the ITT population to 24 months is ongoing.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Roll-in</title>
          <description>The first subject enrolled at each site is considered a roll-in. Data on roll-in subjects were collected through 30 days.</description>
        </group>
        <group group_id="B2">
          <title>Intent to Treat (ITT)</title>
          <description>The Intent to Treat (ITT) population was the primary analysis cohort used to assess the primary safety and effectiveness endpoints. Data on the ITT population was collected through 30 days for primary endpoints. Long-term follow-up for the ITT population to 24 months is ongoing.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="64"/>
            <count group_id="B3" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.3" spread="3.5"/>
                    <measurement group_id="B2" value="75.0" spread="8.0"/>
                    <measurement group_id="B3" value="74.8" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.5" lower_limit="70.5" upper_limit="76.5"/>
                    <measurement group_id="B2" value="74.5" lower_limit="68.5" upper_limit="81.0"/>
                    <measurement group_id="B3" value="73.5" lower_limit="69.0" upper_limit="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced Freedom From MACE Within 30 Days Post-procedure</title>
        <description>The primary safety endpoint was freedom from major adverse cardiac events (MACE) at 30 days - a composite of cardiac death, myocardial infarction (MI) and target vessel revascularization (TVR). The primary endpoints were analyzed using the Intent To Treat (ITT) population.</description>
        <time_frame>Within 30 days of index procedure</time_frame>
        <population>ITT population was the primary analysis cohort; data on roll-in subjects was only collected through 30 days. Data collected from the roll-in subjects were not pre-specified to be reported as a Primary or Secondary Outcome Measure; therefore, only the ITT arm is reported. The ITT population includes all subjects enrolled in the pivotal phase of the study. This population does not include roll-in subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Intent To Treat</title>
            <description>The Intent To Treat (ITT) population was the primary analysis cohort used to assess the primary safety and effectiveness endpoints. Data on the ITT population was collected through 30 days for primary endpoints. Long-term follow-up for the ITT population to 24 months is ongoing.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Freedom From MACE Within 30 Days Post-procedure</title>
          <description>The primary safety endpoint was freedom from major adverse cardiac events (MACE) at 30 days - a composite of cardiac death, myocardial infarction (MI) and target vessel revascularization (TVR). The primary endpoints were analyzed using the Intent To Treat (ITT) population.</description>
          <population>ITT population was the primary analysis cohort; data on roll-in subjects was only collected through 30 days. Data collected from the roll-in subjects were not pre-specified to be reported as a Primary or Secondary Outcome Measure; therefore, only the ITT arm is reported. The ITT population includes all subjects enrolled in the pivotal phase of the study. This population does not include roll-in subjects.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Procedural Success</title>
        <description>The primary effectiveness endpoint was Procedural Success defined as stent delivery with a residual in-stent stenosis &lt;50% (core laboratory assessed) and without in-hospital MACE</description>
        <time_frame>12-24 hours post procedure or at discharge, whichever is earlier, but at least 6 hours post procedure</time_frame>
        <population>ITT population was the primary analysis cohort; data on roll-in subjects was only collected through 30 days. Data collected from the roll-in subjects were not pre-specified to be reported as a Primary or Secondary Outcome Measure; therefore, only the ITT arm is reported. The ITT population includes all subjects enrolled in the pivotal phase of the study. This population does not include roll-in subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Intent To Treat</title>
            <description>The Intent To Treat (ITT) population was the primary analysis cohort used to assess the primary safety and effectiveness endpoints. Data on the ITT population was collected through 30 days for primary endpoints. Long-term follow-up for the ITT population to 24 months is ongoing.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Procedural Success</title>
          <description>The primary effectiveness endpoint was Procedural Success defined as stent delivery with a residual in-stent stenosis &lt;50% (core laboratory assessed) and without in-hospital MACE</description>
          <population>ITT population was the primary analysis cohort; data on roll-in subjects was only collected through 30 days. Data collected from the roll-in subjects were not pre-specified to be reported as a Primary or Secondary Outcome Measure; therefore, only the ITT arm is reported. The ITT population includes all subjects enrolled in the pivotal phase of the study. This population does not include roll-in subjects.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>within 30 days of index procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Coronary IVL System (Roll-In)</title>
          <description>The first subject enrolled at each site is considered a roll-in. Data on roll-in subjects were collected through 30 days.</description>
        </group>
        <group group_id="E2">
          <title>Coronary IVL System (ITT)</title>
          <description>Analysis of the primary endpoints was performed in the ITT population, therefore, only the ITT arm is reported. The ITT population includes all subjects enrolled in the pivotal phase of the study which is ongoing through 24 months. This ITT population does not include roll-in subjects. Data on roll-in subjects were collected through 30 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Retroperitoneal Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <description>Roll-In group does not meet 5% frequency threshold for reporting</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular Access Site Complication</sub_title>
                <description>ITT group does not meet 5% frequency threshold for reporting</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>ITT group does not meet 5% frequency threshold for reporting</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Randee Randoll, Director Clinical Affairs</name_or_title>
      <organization>Shockwave Medical Inc</organization>
      <phone>1-408-577-7856</phone>
      <email>rrandoll@shockwavemedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

